Current issues in the treatment of schizophrenia
Professor Istvan Bitter from Semmelweis University, Budapest, Hungary is sharing his insights on schizophrenia treatment. In the last decades numerous second generation antipsychotics have been introduced. Considering efficacy and safety profiles, how can we personalize treatment? What is the treatment approach for patients with predominant negative symptoms? People with schizophrenia often die prematurely. What are the factors that contribute to this higher mortality rate?
Highlights of EPA 2023
Professor Peter Falkai, past president of the European Psychiatric Association, is sharing his insights on the EPA 2023 Congress, guided by the motto “Social Cohesion, a Common Goal for Psychiatry”. He discussed topics such as the role of loneliness in the development of mental illnesses, the impact of nutrition in the development and prevention of mental illness, as well as the most important novelties in the treatment of schizophrenia.
Novel Pharmacotherapeutic Strategies for Regaining Control over Alcohol Intake in Alcohol Use Disorder
Prof. Benjamin Rolland give us a summary of the session, the most important messages.
Meeting the challenges of schizophrenia care during the COVID-19 pandemic
Prof. Silvana Galderisi speaks about how big is the burden of COVID-19 on patients with schizophrenia. What are the greatest challenges for physicians and care givers?
Consequences of COVID-19 Outbreak on Mental Health
Prof. Celso Arango speaks about the lessons he learned from coronavirus health crisis in Spain. He shares the most important findings and messages of his presentation.
Obstetric Complications: The Forgotten Risk Factor for Schizophrenia
Birth Asphyxia: Is this an area of primary pevention in schizophrenia? Prof. Robin Murray speaks about the most important findings of his presentation.
Difficult to Treat Depression
Prof. Andrea Fiorillo speaks about the newest novelties on the treatment of depression.
Prof. Axel Börsch-Supan speaks about the most important findings of the Survey of Health, Ageing and Retirement in Europe (SHARE).
Highlights of the EPA 2021
Prof. Peter Falkai, the newly elected President of EPA summarize the highlights of the recent congress.
Antipsychotic treatment: polypharmacy is better than monotherapy – PRO
Guidance for treatment of ADHD in adults
ADHD in adults
Functional recovery in depression: role of cognitive symptoms
Treatment of schizophrenia negative symptoms: Do we have an adequate solution?
Schizophrenia is a Myth with a Strong Genetic Component
Cybersuicide in young people: implications for suicide prevention
The EPA 2020 congress is going virtual